SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

BridgeBio Pharma reports primary endpoint achieved in 76% of CALIBRATE patients

A presentation on encaleret reports that 76% of patients in the CALIBRATE study achieved the primary endpoint.

BBIO

Related stories